WIPO logo
Mobile | Deutsch | English | Español | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Recherche dans les collections de brevets nationales et internationales
World Intellectual Property Organization
Recherche
 
Options de navigation
 
Traduction
 
Options
 
Quoi de neuf
 
Connexion
 
Aide
 
maximize
Traduction automatique
1. (WO2006053170) SUCRES ET/OU POLYSACCHARIDES POUR L'INHIBITION ET/OU TRAITEMENT D'INFECTIONS VAGINALES
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WHAT IS CLAIMED IS:
1. A method for inhibiting and/or treating vaginal infection, the method comprising topically administering a vaginal treatment composition to the vagina of a female, the vaginal treatment composition comprising an effective amount of at least one therapeutic agent selected from the group consisting of sugars and sugar alcohols, and further wherein the vaginal treatment composition has an osmolarity of from about 270 to about 310 milliosmoles per liter.
2. The method of claim 1 , wherein the therapeutic agent inhibits the growth of Trichomonas vaginalis, Candida albicans, Gardnerella vaginalis, or
combinations thereof.
3. The method of claim 1 , wherein the therapeutic agent is a hexose alcohol selected from the group consisting of glycerol, meso-galacitol (dulcitol), inositol, D-mannitol, D-sorbitol, and isomers thereof.
4. The method of claim 1 , wherein the therapeutic agent is a pentose alcohol selected from the group consisting of D-xylitol, D-arabitol, meso-ribitol

(adonitol), and isomers thereof.
5. The method of claim 4, wherein the pentose alcohol is D-xylitol or an isomer thereof.
6. The method of claim 1 , wherein the therapeutic agent is a pentose sugar selected from the group consisting of D-arabinose, D-ribose, D-ribulose, D-xylose,

D-xylulose, D-lyxose, and isomers thereof.
7. The method of claim 6, wherein the pentose sugar is D-ribose.
8. The method of claim 1 , wherein the therapeutic agent is a hexose sugar selected from the group consisting of D-galactose, D-inositose, D-mannose, and isomers thereof.
9. A method for inhibiting and/or treating trichomonas vaginitis, the method comprising topically administering a vaginal treatment composition to the vagina of a female, the vaginal treatment composition comprising an effective amount of at least one therapeutic agent that inhibits the growth of Trichomonas vaginalis, wherein the therapeutic agent is selected from the group consisting of pentose sugars and pentose alcohols.
10. A method for inhibiting and/or treating bacterial vaginosis, the method comprising topically administering a vaginal treatment composition to the vagina of a female, the vaginal treatment composition comprising an effective amount of at least one therapeutic agent that inhibits the growth of Gardnerella vaginalis, wherein the therapeutic agent is selected from the group consisting of pentose sugars and pentose alcohols.
11. The method of claim 9 or 10, wherein the vaginal treatment composition has an osmolarity of from about 270 to about 310 milliosmoles per liter.
12. The method of any of claims 9 to 11 , wherein the therapeutic agent is a pentose alcohol selected from the group consisting of D-xylitol, D-arabitol, meso-ribitol (adonitol), and isomers thereof.
13. The method of claim 12, wherein the pentose alcohol is D-xylitol or an isomer thereof.
14. The method of any of claims 9 to 11 , wherein the therapeutic agent is a pentose sugar selected from the group consisting of D-arabinose, D-ribose, D-ribulose, D-xylose, D-xylulose, D-lyxose, and isomers thereof.
15. The method of claim 14, wherein the pentose sugar is D-ribose.
16. The method of any of the foregoing claims, wherein the therapeutic agent comprises from about 0.2 wt/vol% to about 5 wt/vol%, and preferably from about 0.5 wt/vol% to about 4.5 wt/vol% of the vaginal treatment composition.
17. The method of any of the foregoing claims, wherein the vaginal treatment composition has an osmolarity of from about 280 to about 300
milliosmoles per liter.
18. The method of any of the foregoing claims, wherein the vaginal treatment composition is substantially free of additional tonicity agents.
19. The method of any of the foregoing claims, wherein the vaginal treatment composition has a pH of from about 2.0 to about 5.5.
20. The method of any of the foregoing claims, wherein the therapeutic agent does not substantially inhibit the growth of Lactobacillus acidophilus.